Heparin Market 2030: The Rise of Innovative Therapies in Asia Pacific

The global heparin market was valued at approximately USD 7.56 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 2.7% from 2024 to 2030. A significant driver behind this market expansion is the rising prevalence of chronic diseases. According to a WHO article published in September 2023, noncommunicable diseases (NCDs), which include chronic diseases, are responsible for approximately 41 million deaths each year. Of these, cardiovascular diseases (CVDs) account for 17.9 million deaths, cancer causes 9.3 million deaths, chronic respiratory diseases contribute to 4.1 million deaths, and diabetes, including complications from diabetes-related kidney diseases, leads to an additional 2 million deaths. This growing burden of chronic conditions is expected to boost the demand for heparin, a critical anticoagulant used in treating various health conditions. In addition to this, factors such as the increasing demand for whole blood and blood component transfusions, a growing elderly population, and the rising use of plasma in the pharmaceutical industry are all expected to further drive the growth of the heparin market.

As the elderly population continues to grow, there is an increasing need for medical treatments involving heparin, especially to prevent blood clots during medical procedures commonly required by older individuals. A WHO report published in October 2023 highlights that the global population over the age of 60 is steadily rising, with the number of individuals in this age group expected to double to 2.1 billion by 2050. As people live longer, the likelihood of age-related health issues, many of which necessitate the use of heparin, increases. Heparin is essential in preventing blood clot formation, which is especially important during surgeries or treatments for age-related conditions such as heart disease, stroke, and diabetes. This demographic shift, driven by the aging global population, presents both challenges and opportunities. The demand for heparin is expected to surge as healthcare needs for the elderly become more pronounced, positioning the aging population as a key factor driving the market's growth. As healthcare systems adapt to the increasing needs of older adults, heparin's role in medical treatments will become increasingly vital.

Gather more insights about the market drivers, restrains and growth of the Heparin Market

Regional Insights

North America Heparin Market Trends

In 2023, North America led the global heparin market, capturing a substantial 38.6% share. This dominance is largely attributed to several key factors, including rising patient awareness, a high disease burden, proactive government policies, advancements in healthcare technology, and continuous improvements in healthcare infrastructure. The presence of major pharmaceutical and healthcare companies in the region further accelerates market growth. According to a CDC article published in May 2023, heart disease remains the leading cause of death in the United States, claiming one life every 33 seconds. This alarming statistic highlights the critical role of heparin, particularly as an anticoagulant used to manage and treat cardiovascular diseases (CVDs), a key contributor to the market's sustained demand. The high incidence of heart disease in the region underscores the ongoing need for heparin in medical treatments, which directly supports the continued growth of the market in North America.

Asia Pacific Heparin Market Trends

In contrast, the Asia Pacific region is expected to experience the fastest compound annual growth rate (CAGR) from 2024 to 2030. Cardiovascular diseases (CVDs) are the leading cause of both death and disability in the region, placing significant economic strain on local healthcare systems. The rising prevalence of CVDs in Asia is an increasing concern, with a large population affected by various cardiovascular conditions. According to a report published by the NCBI in June 2023, "The Report on Cardiovascular Health and Diseases in China 2021: An Updated Summary," approximately 330 million people in China are impacted by cardiovascular diseases. This staggering figure not only highlights the urgent need for effective treatments, such as heparin, but also points to the economic and healthcare challenges the region faces as it strives to address the growing burden of heart disease. Given the high incidence of CVD in the region and the expanding healthcare infrastructure, the demand for heparin in Asia Pacific is expected to grow rapidly, making it a key market to watch in the coming years.

Browse through Grand View Research's Category Pharmaceuticals Industry Research Reports.

The global hormone replacement therapy market size was valued at USD 21.28 billion in 2022 and is expected to grow at a compounded annual growth rate (CAGR) of 6.6% from 2023 to 2030.
The global pneumonia therapeutics market size was valued at USD 2.28 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 9.4% from 2024 to 2030.

Key Companies & Market Share Insights

Pfizer Inc.; LEO Pharma A/S; and Sanofi are some of the dominant market players.
Pfizer, Inc. is a pharmaceutical company based in the U.S. and founded in 1849. It manufactures products for curing a wide range of medical disciplines, including diabetes, immunology, cardiology, oncology, dermatological diseases, rare diseases, inflammatory diseases, oncology, and vaccines.
Sanofi was incorporated in 1994 and is headquartered in France. It engages in R&D, manufacturing g, and marketing of therapeutic solutions, comprising diabetes, human vaccines, innovative drugs, consumer healthcare, CVD, internal medicine, immunology, neurology, thrombosis, oncology, arthritis, central nervous system, osteoporosis, primary healthcare, vaccines, animal health, and Genzyme.
B. Braun Medical, Inc.; Sandoz (Novartis AG); and Aspen Holdings are some of the emerging market players
Novartis AG is a Swiss-based multinational company involved in R&D, manufacturing, and marketing of healthcare products. The company was formed following the merger of Sandoz Laboratories, Inc. and Ciba-Geigy AG. It is a publicly held organization and operates through two segments: Innovative Medicines and Sandoz.
B. Braun Medical, Inc. is involved in developing, manufacturing, and marketing innovative medical products & services. The company was established in 1839 and is headquartered in Germany.

Key Heparin Companies: